SAI MedPartners Buys Custom Pharma Researcher Fulcrum

Pharma and biotech insight and analytics firm SAI MedPartners has acquired Waltham, MA-based primary MR firm Fulcrum Research Group, which also focuses on the healthcare and biopharma sectors.

SAI is headquartered in Reading, PA and provides strategic insights and analytics to the pharmaceutical, biotechnology and medical device industries across the product development lifecycle. Management of the company partnered with Northlane Capital Partners in June last year to acquire it.

Fulcrum, founded a dozen years ago, designs custom market research through direct physician and patient interviews and surveys, focusing on market dynamics, competitive advantages, product positioning and the patient journey. Its senior team including founders Erik Coats, Kelly Marino and Lucy Robin will remain in place following the transaction.

Erik Nordhoy (pictured), founder and CEO of SAI, says the two firms 'share the same values and commitment to analytical research and top tier client service', adding: 'Fulcrum complements SAI's core competitive intelligence expertise and enhances our value proposition as a full-service decision support partner to the pharmaceutical and biotech sectors'. Erik Coats, Managing Partner of Fulcrum, says SAI is an ideal partner for the next stage of Fulcrum's growth: 'it provides the opportunity to continue providing our best-in-class market research services, while also leveraging the capabilities and relationships of the SAI platform to augment our services to new and existing clients'.

SAI has a presence across the USA, Europe and Asia, and is online at www.sai-med.com .